Denosumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Denosumab and local guidelines before prescribing.
Mechanism
RANKL monoclonal antibody inhibiting osteoclasts.
Uses
Osteoporosis, bone metastases, giant-cell tumour of bone, hypercalcaemia of malignancy (refractory).
Dosing
- Vitamin D: 800–1,000 units daily for people with or at risk of osteoporosis, and for housebound or care-home residents. Check and replace vitamin D before starting IV bisphosphonates or denosumab, to avoid hypocalcaemia.
Endocrinology: Bone Medicine - Bone-targeted drugs to reduce skeletal events - zoledronic acid 4 mg IV every 3–4 weeks or denosumab 120 mg SC every 4 weeks (oncology doses). Note the higher ONJ risk at these doses.
Endocrinology: Bone Medicine - Denosumab (osteoporosis) | 60 mg SC every 6 months. Check calcium and vitamin D. Never stop or delay without a bisphosphonate plan (rebound vertebral fractures).
Endocrinology: Bone Medicine - Denosumab (bone metastases) | 120 mg SC every 4 weeks, with calcium and vitamin D. Higher ONJ risk.
Endocrinology: Bone Medicine
Side effects
Hypocalcaemia, hypophosphataemia, osteonecrosis of the jaw, atypical femoral fracture, infection; rebound vertebral fractures on stopping.
Interactions
Few drug interactions.
Contraindications and cautions
Hypocalcaemia (uncorrected)
Monitoring
Calcium (especially in renal impairment), dental health
Pregnancy and breastfeeding
Avoid; contraception during treatment
Renal and hepatic impairment
No adjustment but higher hypocalcaemia risk in CKD
Overdose and reversal
Supportive; correct calcium
Special advice
Replace calcium and vitamin D; never stop abruptly without follow-on bisphosphonate; dental review before starting.
More from the textbook: uses, cautions and other points
- Correct vitamin D before starting bisphosphonates or denosumab (risk of hypocalcaemia).
Endocrine: Anatomy Physiology and Pharmacology - Hypercalcaemia treatment - IV fluids (0.9% saline) first, then IV bisphosphonate; steroids if vitamin D-driven (sarcoidosis, lymphoma); denosumab or calcitonin in some cases.
Endocrine: Anatomy Physiology and Pharmacology - Denosumab | RANKL antibody every 6 months; hypocalcaemia; rebound fractures if stopped.
Endocrine: Anatomy Physiology and Pharmacology - Multiple vertebral fractures a year after stopping an osteoporosis injection | Denosumab rebound
Endocrine: Anatomy Physiology and Pharmacology - 5. A 72-year-old woman has a hip fracture. Adjusted calcium 2.18, eGFR 28, vitamin D 18 nmol/L. The team want to start denosumab. Answer: Correct vitamin D and calcium first.
Endocrine: Anatomy Physiology and Pharmacology - Vitamin D loading and calcium; recheck calcium before the first dose - denosumab can cause severe hypocalcaemia, especially in CKD.
Endocrine: Anatomy Physiology and Pharmacology - Explain that denosumab must not be stopped or delayed without a plan (rebound vertebral fractures); falls assessment and dental check.
Endocrine: Anatomy Physiology and Pharmacology - Denosumab - check calcium; never stop without a plan.
Endocrine: Anatomy Physiology and Pharmacology
Where it is discussed in the book
- Endocrine: Anatomy Physiology and Pharmacology (9 mentions)
- Endocrinology: Emergencies (1 mention)
- Endocrinology: Bone Medicine (28 mentions)
- Renal: Anatomy, Physiology and Pharmacology (1 mention)
- Renal: Chronic Kidney Disease (1 mention)
- Haematology: Myeloma and Lymphoma (1 mention)
- Oncology: Emergencies (3 mentions)
- Oncology: Urology and Genital cancers (1 mention)
- Oncology: Breast and Gynae Cancers (2 mentions)
- Palliative: Symptoms Management (1 mention)
- Rheumatology Anatomy Physiology Pharmacology (8 mentions)
- Rheumatology: Emergencies, pregnancy and other systemic diseases (1 mention)
- ENT Anatomy Physiology (1 mention)
- Surgey: Trauma and orthopaedics (1 mention)
- Medicine of the older adult.: Falls, syncope, mobility and fragility fractures (4 mentions)
- Acute Medicine: Electrolytes, acid–base, AKI and metabolic emergencies (3 mentions)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)
- General Practice: Long-term conditions, multimorbidity and polypharmacy (1 mention)
- Physiology: Cells, tissues, homeostasis, fluids and acid–base balance (2 mentions)
- 0230 (1 mention)